keyword
MENU ▼
Read by QxMD icon Read
search

Hodgkins disease

keyword
https://www.readbyqxmd.com/read/28811872/current-and-emerging-treatment-options-for-mantle-cell-lymphoma
#1
REVIEW
Bita Fakhri, Brad Kahl
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with typically aggressive behavior. The genetic signature is the chromosomal translocation t(11;14)(q13;q32) resulting in overexpression of cyclin D1. Asymptomatic newly diagnosed MCL patients with low tumor burden can be closely observed, deferring therapy to the time of disease progression. Although MCL classically responds to upfront chemotherapy, it remains incurable with standard approaches. For patients in need of frontline therapy, the initial decision is whether to proceed with an intensive treatment strategy or a non-intensive treatment strategy...
August 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/28809998/temporal-association-of-herpes-zoster-eruption-post-aminolevulinic-acid-hydrochloride-photodynamic-therapy-for-actinic-keratoses
#2
Katie Manno, Joel L Cohen
<p>Herpes zoster is a common and painful disease caused by the reactivation of the varicella-zoster virus with a higher incidence and severity associated with increasing age as well as compromised immune status. Acute inciting events for this eruption are not always known, but can include illness, stress, and mechanical injury. Photodynamic therapy (PDT) is a widely used treatment modality for precancerous skin lesions that has not been previously associated with provoking a herpes zoster outbreak. We present a case of herpes zoster eruption occurring after PDT for actinic keratoses in a patient with Non-Hodgkin Lymphoma (NHL)...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28809079/changes-in-the-use-of-erythropoiesis-stimulating-agents-esas-and-red-blood-cell-transfusion-in-patients-with-cancer-amidst-regulatory-and-reimbursement-changes
#3
Prasad L Gawade, Jesse A Berlin, David H Henry, Dianne Tomita, Barry D Brooks, Janet Franklin, Brian D Bradbury, Cathy W Critchlow
PURPOSE: Evaluate changes in use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in cancer patients receiving myelosuppressive chemotherapy following regulatory and reimbursement actions. METHODS: Calendar year patient cohorts (2005-2013) with breast, colorectal, lung, multiple myeloma, non-Hodgkin lymphoma, ovarian, or prostate cancer and receiving myelosuppressive chemotherapy were identified within the Marketscan database. Incidence of ESA treatment and transfusion were estimated in each year, as was median number of ESA administrations...
August 14, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28805662/clinical-and-immunological-responses-after-cd30-specific-chimeric-antigen-receptor-redirected-lymphocytes
#4
Carlos A Ramos, Brandon Ballard, Huimin Zhang, Olga Dakhova, Adrian P Gee, Zhuyong Mei, Mrinalini Bilgi, Meng-Fen Wu, Hao Liu, Bambi Grilley, Catherine M Bollard, Bill H Chang, Cliona M Rooney, Malcolm K Brenner, Helen E Heslop, Gianpietro Dotti, Barbara Savoldo
BACKGROUND: Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS: We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30...
August 14, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28799436/immunotherapy-based-approaches-in-myelofibrosis
#5
Lucia Masarova, Srdan Verstovsek, Hagop Kantarjian, Naval Daver
Aberrant regulation of the immune system with up-regulation of pro-inflammatory cytokines contributes to disease pathophysiology in myelofibrosis (MF). Therapeutic options for MF associated anemia, thrombocytopenia, and bone marrow fibrosis remain limited. Areas covered: This review focuses on immune based therapies in MF, including immunomodulatory imide drugs (IMiDs), interferons, monoclonal antibodies and targeted agents (SL-401), and checkpoint inhibitors. Published literature was reviewed using available databases (PubMed, Cochrane, Scopus) and web pages (clinicaltrials...
August 11, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28798034/fdg-pet-ct-in-lymphoma-has-imaging-directed-personalized-medicine-become-a-reality
#6
Sally F Barrington, Peter Wm Johnson
Positron emission tomography with computed tomography (PET-CT) using (18)F- fluorodeoxyglucose (FDG) is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the five-point 'Deauville scale', have enabled PET to become a surrogate for treatment success/failure in common lymphoma subtypes. This review summarizes the key evidence from clinical trials that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28798005/hodgkin-s-lymphoma-as-a-multiloculated-lung-cavity-lesion
#7
Aisha M Al-Osail, Hind S Al-Saif, Mashail M Al-Hajri, Hajer M Al-Zuhair, Deemah A Al-Abdulhadi, Emad M Al-Osail, Sarah M Al-Hajri
BACKGROUND: Pulmonary manifestation of Hodgkin's lymphoma is common, and recently, single and/or multiple lung cavities with air-fluid levels has been reported as a primary manifestation of Hodgkin's lymphoma. However, the unusual presentation of the lung cavity itself has not been previously reported for Hodgkin's lymphoma, especially as the first presentation of the disease. CASE PRESENTATION: We report a 16-year-old male who presented to the emergency department with chief complaints of fever, unintentional 10-kilogram weight loss, a productive cough and pulmonary cavity for investigation...
May 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28796966/adult-t-cell-leukemia-lymphoma
#8
Neha Mehta-Shah, Lee Ratner, Steven M Horwitz
Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative neoplasm caused by human T-lymphotrophic virus 1. In its more common, aggressive forms, ATL carries one of the poorest prognoses of the non-Hodgkin lymphomas. The disease has clinical subtypes (ie, acute, lymphoma, chronic, and smoldering forms) defined by the presenting features, and therefore, the clinical course can vary. For the smoldering and lower-risk chronic forms, combinations involving antiviral therapies have shown some success...
August 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28795661/molecular-diversity-of-igg-responses-to-epstein-barr-virus-proteins-in-asymptomatic-epstein-barr-virus-carriers
#9
Ria Goswami, Kathy Ho Yen Shair, Edward Gershburg
The Epstein-Barr virus (EBV) is a ubiquitous pathogen that infects over 90 % of adults. EBV is the primary etiological agent of infectious mononucleosis and is closely associated with nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma and Burkitt lymphoma. Clinical serological assays for EBV diagnosis only survey a small portion of the viral proteome, which does not represent the total antigenic breadth presented to the immune system during viral infection. In this study, we have generated an expression library containing the majority of EBV ORFs, and have systematically evaluated IgG responses to those EBV proteins in sera from EBV carriers...
August 10, 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28789664/mycobacterium-iranicum-bacteremia-and-hemophagocytic-lymphohistiocytosis-a-case-report
#10
Simon Grandjean Lapierre, Alexandre Toro, Michel Drancourt
BACKGROUND: Mycobacterium iranicum has recently been recognised as an opportunistic human pathogen. Although infectious conditions represent frequent triggers for hemophagocytic lymphohistiocytosis, non-tuberculous mycobacterial infections are rarely associated with this entity. To this date, M. iranicum infection has never been reported in France, has never been associated with hemophagocytic lymphohistiocytosis and has never been found to be multi-resistant on standardized antimicrobial susceptibility testing...
August 8, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28776551/advances-in-pathobiology-of-primary-central-nervous-system-lymphoma
#11
REVIEW
Xue-Liang Yang, Yuan-Bo Liu
OBJECTIVE: Primary central nervous system lymphoma (PCNSL) is a specific type of non-Hodgkin lymphoma with poor prognosis. The rare incidence of this disease and difficulty to obtain sufficient tissue material impede deep research into PCNSL. However, application of modern molecular techniques makes it possible to find biological characteristics exclusive to PCNSL. Therefore, we systematically reviewed the latest research progress on biological characteristics and pathogenesis of PCNSL...
August 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28776363/development-of-hodgkin-lymphoma-in-a-patient-with-sarcoidosis
#12
F Gediz, A F Yilmaz, B Payzin, T Yuksel, A O Calli, S Kobak
Sarcoidosis is a chronic granulomatous disease of unknown etiology characterized by non-caseified granulomas in many different organs and systems. The disease most frequently manifests with bilateral hilar lymphadenopathy and infiltrations in the lungs and skin, as well as with eye lesions. It may mimic a number of systemic diseases and/or accompany them. The development of lymphoma in patients with sarcoidosis or the co-occurrence of both diseases is rarely reported in the literature. In this paper we report a female patient followed up with sarcoidosis for three years who developed Hodgkin lymphoma, according to the results of the investigations and biopsy results...
August 3, 2017: Reumatismo
https://www.readbyqxmd.com/read/28774879/outcomes-in-refractory-diffuse-large-b-cell-lymphoma-results-from-the-international-scholar-1-study
#13
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew J Maurer, Lynn Navale, Jeff Wiezorek, William Y Go, Christian Gisselbrecht
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. The international, multicohort retrospective non-Hodgkin lymphomaresearch (SCHOLAR-1) study retrospectively evaluated outcomes in patients with refractory DLBCL, which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed ≤12 months of autologous stem cell transplantation...
August 3, 2017: Blood
https://www.readbyqxmd.com/read/28774170/an-autopsy-case-of-epstein-barr-virus%C3%A2-associated-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system-in-an-immunocompromised-host
#14
Sun-Young Park, Seong Ik Kim, Hannah Kim, Yoojin Lee, Sung-Hye Park
Lymphomas arising in the central nervous system (CNS) of immunocompromised hosts represent non-Hodgkin's lymphomas exclusively associated with Epstein-Barr virus (EBV). Here we report an autopsy case of EBV-associated CNS diffuse large B-cell lymphoma (DLBCL) in a host suffering from systemic lupus erythematosus who underwent immunosuppressive therapy. After autopsy, EBV-associated CNS DLBCL as well as pulmonary mixed aspergillosis and Pneumocystis jirovecii pneumonia were added to the clinical impressions of complicated pneumonia and cerebral hemorrhage in this immunocompromised patient...
August 4, 2017: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/28761603/-malignant-non-hodgkin-s-lymphoma-of-the-breast-and-hiv-about-a-case
#15
Ahmed Meklaa, Abdennasser El Kharass
Malignant non-Hodgkin's lymphoma (NHL) accounts for 0.5% of all breast cancers. Diagnosis is essentially based on histology. We report the case of a 42-year old female patient with MNHL of the breast and positive HIV serology. This study aimed to highlight the clinical, radiological and therapeutic aspects of this disease and to emphasize the importance of HIV testing in patients with extraganglionar MNHL.
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28760309/autologous-stem-cell-transplant-still-the-standard-for-fit-patients-with-mantle-cell-lymphoma
#16
REVIEW
Ashley D Staton, Amelia A Langston
Mantle cell lymphoma is a relatively rare malignancy, comprising fewer than 10% of all non-Hodgkin lymphomas. It is a heterogeneous disease, and although most patients experience an aggressive clinical course, some have a more indolent disease and may not require immediate therapy. There are currently few reliable prognostic markers, making it difficult to accurately predict which patients require early intensive treatment. We argue that consolidative autologous stem cell transplantation in first remission remains the standard of care for the young and fit patient population, based on long-term data from phase II and III trials demonstrating that early transplantation extends both progression-free and overall survival...
July 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28760308/real-life-experience-for-integration-of-pet-ct-in%C3%A2-the-treatment-of-hodgkin-lymphoma-in%C3%A2-lebanon
#17
Riwa Sakr, Marcel Massoud, Fouad Kerbage, Layale Rached, Jean Zeghondy, Elie Akoury, Fady Nasr, Georges Chahine
BACKGROUND: Hodgkin lymphoma (HL) is a highly curable disease; < 80% of patients will achieve long-term survival. Positron emission tomography-computed tomography (PET-CT) has played a major role in the evaluation of both disease staging and response and has become an essential component in tailoring patients' treatment. We report the effect of integrating PET-CT into the management of HL in Lebanon. PATIENTS AND METHODS: We analyzed the data regarding the usage of PET-CT at diagnosis, during treatment (interim PET), and at the end of treatment...
July 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28760307/survival-pattern-of-hodgkin-lymphoma-patients-in-the-last-25-years-in-lebanon
#18
Marcel Massoud, Fouad Kerbage, Joseph Nehme, Riwa Sakr, Layale Rached, Jean Zeghondy, Fady Nasr, Georges Chahine
CONTEXT: After the emergence of combination chemotherapy in 1960s, survival of patients with Hodgkin lymphoma (HL) has dramatically improved worldwide. We lack studies that document the favorable evolution of survival regarding this disease in Lebanon. OBJECTIVE: To compare the overall survival in HL over 3 different decades in Lebanon. METHODS: We retrospectively reviewed the charts of 196 patients diagnosed with HL, treated and followed from 1990 to 2015 in our center...
July 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28760045/hodgkin-lymphoma-in-children-adolescents-and-young-adults-a-comparative-study-of-clinical-presentation-and-treatment-outcome
#19
Annika Englund, Ingrid Glimelius, Klaus Rostgaard, Karin E Smedby, Sandra Eloranta, Daniel Molin, Thomas Kuusk, Peter de Nully Brown, Peter Kamper, Henrik Hjalgrim, Gustaf Ljungman, Lisa Lyngsie Hjalgrim
BACKGROUND: Hodgkin lymphoma (HL) treatment protocols for children, adolescents and young adults traditionally differ, but the biological and clinical justification for this remains uncertain. MATERIAL AND METHODS: We compared age-dependent clinical presentation and treatment and outcome for 1072 classical HL patients 0-24 years diagnosed in Denmark (1990-2010) and Sweden (1992-2009) in pediatric (n = 315, Denmark <15 years, Sweden <18 years) or adult departments (n = 757)...
August 1, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28758262/paraneoplastic-pemphigus-seen-in-4-patients-with-hematologic-malignancies-formerly-treated-with-rituximab
#20
C Baykal, S Kılıç, R Küçükoğlu
Paraneoplastic pemphigus (PNP) is a peculiar variant of pemphigus with pathognomonic clinical, histological, and immunological features. It is typically associated with hematologic malignancies (84%), such as non-Hodgkin lymphomas (NHL) (most common), chronic lymphocytic leukemia (CLL), Castleman disease, thymoma, Waldenström's macroglobulinemia, Hodgkin lymphoma, and monoclonal gammopathy, as well as non-hematological neoplasms, such as epithelial carcinomas, mesenchymal sarcomas, and malignant melanoma. This article is protected by copyright...
July 31, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
46636
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"